Ovid Therapeutics Stock Analysis

OVID Stock  USD 0.74  0.01  1.37%   
Ovid Therapeutics is overvalued with Real Value of 0.71 and Hype Value of 0.74. The main objective of Ovid Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Ovid Therapeutics is worth, separate from its market price. There are two main types of Ovid Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Ovid Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Ovid Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.

Ovid Stock Analysis Notes

About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.69. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Ovid Therapeutics recorded a loss per share of 0.46. The entity had not issued any dividends in recent years. Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was incorporated in 2014 and is headquartered in New York, New York. Ovid Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people. To find out more about Ovid Therapeutics contact Zoology Dphil at 646 661 7661 or learn more at https://www.ovidrx.com.

Ovid Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ovid Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ovid Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ovid Therapeutics generated a negative expected return over the last 90 days
Ovid Therapeutics has some characteristics of a very speculative penny stock
Ovid Therapeutics has high historical volatility and very poor performance
Ovid Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 391.69 K. Net Loss for the year was (52.34 M) with profit before overhead, payroll, taxes, and interest of 631.7 K.
Ovid Therapeutics currently holds about 152.37 M in cash with (45.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 56.0% of the company shares are owned by institutional investors

Ovid Therapeutics Upcoming and Recent Events

11th of March 2024
Upcoming Quarterly Report
View
3rd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
11th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Ovid Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 52.55 M.

Technical Drivers

As of the 21st of January, Ovid Therapeutics holds the Coefficient Of Variation of (514.54), variance of 12.95, and Risk Adjusted Performance of (0.15). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Ovid Therapeutics, as well as the relationship between them. Please check Ovid Therapeutics standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and kurtosis to decide if Ovid Therapeutics is priced some-what accurately, providing market reflects its current price of 0.74 per share. As Ovid Therapeutics is a penny stock we also suggest to check out its jensen alpha numbers.

Ovid Therapeutics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Ovid Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Ovid Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Ovid Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ovid Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ovid Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ovid Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Jeffrey Rona few days ago
Acquisition by Jeffrey Rona of 175000 shares of Ovid Therapeutics at 2.82 subject to Rule 16b-3
 
Bernstein Karen over a month ago
Acquisition by Bernstein Karen of 90000 shares of Ovid Therapeutics at 1.06 subject to Rule 16b-3
 
Williams Douglas E over two months ago
Acquisition by Williams Douglas E of 13250 shares of Ovid Therapeutics at 5.29 subject to Rule 16b-3
 
Friedman Bart over two months ago
Acquisition by Friedman Bart of 69424 shares of Ovid Therapeutics subject to Rule 16b-3
 
Alexander Margaret A. over three months ago
Disposition of 70000 shares by Alexander Margaret A. of Ovid Therapeutics at 3.73 subject to Rule 16b-3
 
Perone Thomas Michael over three months ago
Acquisition by Perone Thomas Michael of 175000 shares of Ovid Therapeutics at 2.72 subject to Rule 16b-3
 
Jeffrey Rona over six months ago
Acquisition by Jeffrey Rona of 175000 shares of Ovid Therapeutics at 2.5 subject to Rule 16b-3
 
Friedman Bart over six months ago
Acquisition by Friedman Bart of 69424 shares of Ovid Therapeutics subject to Rule 16b-3
 
Takeda Pharmaceutical Co Ltd over six months ago
Acquisition by Takeda Pharmaceutical Co Ltd of 1250 shares of Ovid Therapeutics subject to Rule 16b-3
 
Poole Robert Michael over six months ago
Acquisition by Poole Robert Michael of 30000 shares of Ovid Therapeutics at 3.94 subject to Rule 16b-3
 
Timothy Daly over six months ago
Acquisition by Timothy Daly of 125000 shares of Ovid Therapeutics at 2.82 subject to Rule 16b-3
 
Jeremy Levin over six months ago
Acquisition by Jeremy Levin of 18248 shares of Ovid Therapeutics at 2.76 subject to Rule 16b-3

Ovid Therapeutics Outstanding Bonds

Ovid Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ovid Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ovid bonds can be classified according to their maturity, which is the date when Ovid Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Ovid Therapeutics Predictive Daily Indicators

Ovid Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ovid Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Ovid Therapeutics Forecast Models

Ovid Therapeutics' time-series forecasting models are one of many Ovid Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ovid Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Ovid Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ovid Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ovid shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Ovid Therapeutics. By using and applying Ovid Stock analysis, traders can create a robust methodology for identifying Ovid entry and exit points for their positions.
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was incorporated in 2014 and is headquartered in New York, New York. Ovid Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Ovid Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Fundamental Analysis Now

   

Fundamental Analysis

View fundamental data based on most recent published financial statements
All  Next Launch Module

Complementary Tools for Ovid Stock analysis

When running Ovid Therapeutics' price analysis, check to measure Ovid Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ovid Therapeutics is operating at the current time. Most of Ovid Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ovid Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ovid Therapeutics' price. Additionally, you may evaluate how the addition of Ovid Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Correlations
Find global opportunities by holding instruments from different markets